Table 4. Multivariate analysis for overall survival in MDS patients treated with HMA therapy.

Model 1				Reduced Model
	HR	95% CI	P –value	HR	95% CI	P –value
TP53 mutation (mutated vs. WT)	3.31	1.20-9.08	0.02	3.01	1.58-5.69	0.0007
IPSS-R risk (high/very high vs. very low/low/intermediate)	2.24	1.04-4.83	0.04	2.31	1.08-4.94	0.03
Therapy-related (yes vs. de novo)	1.79	0.98-3.28	0.06
Monosomal karyotype (monosomal vs. non-monosomal)	0.86	0.31-2.40	0.77
Model 2
	HR	95% CI	P –value
TP53 mutation (mutated vs. WT)	3.66	1.53-8.75	0.004
IPSS-R risk (high/very high vs. very low/low/intermediate)	2.35	1.08-5.12	0.03
Therapy-related (yes vs. de novo)	1.77	0.97-3.23	0.06
Complex karyotype (complex vs. non-complex)	0.73	0.3-1.75	0.47